BRUSSELS, BELGIUM--(Marketwire - March 31, 2008) - Results provide evidence of CDP791’s biological activity. Positive trends were observed on several efficacy endpoints. Data are encouraging in supporting further clinical development of CDP791 in first line non-small cell lung cancer. UCB is evaluating partnership options.
